In vitro and in vivo drug interactions involving human CYP3A

被引:692
作者
Thummel, KE [1 ]
Wilkinson, GR
机构
[1] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA
[2] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA
关键词
drug metabolism; first-pass metabolism; enzyme inhibition; enzyme induction;
D O I
10.1146/annurev.pharmtox.38.1.389
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P4503A (CYP3A) is importantly involved in the metabolism of many chemically diverse drugs administered to humans. Moreover, its localization in high amounts both in the small intestinal epithelium and liver makes it a major contributor to presystemic elimination following oral drug administration. Drug interactions involving enzyme inhibition or induction are common following the coadministration of two or more CYP3A substrates. Studies using in vitro preparations are useful in identifying such potential interactions and possibly permitting extrapolation of in vitro findings to the likely in vivo situation. Even if accurate quantitative predictions cannot be made, several classes of drugs can be expected to result in a drug interaction based on clinical experience. In many instances, the extent of such drug interactions is sufficiently pronounced to contraindicate the therapeutic use of the involved drugs.
引用
收藏
页码:389 / 430
页数:42
相关论文
共 278 条
  • [51] Fleishaker JC, 1996, J PHARMACOL EXP THER, V277, P991
  • [52] Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
    Floren, LC
    Bekersky, I
    Benet, LZ
    Mekki, Q
    Dressler, D
    Lee, JW
    Roberts, JP
    Hebert, MF
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (01) : 41 - 49
  • [53] Franklin MR, 1995, DRUG METAB DISPOS, V23, P1379
  • [54] Fromm MF, 1996, HEPATOLOGY, V24, P796
  • [55] INVITRO FORECASTING OF DRUGS WHICH MAY INTERFERE WITH THE BIOTRANSFORMATION OF MIDAZOLAM
    GASCON, MP
    DAYER, P
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (06) : 573 - 578
  • [56] THE INCREASE IN URINARY-EXCRETION OF 6-BETA-HYDROXYCORTISOL AS A MARKER OF HUMAN HEPATIC CYTOCHROME-P450IIIA INDUCTION
    GED, C
    ROUILLON, JM
    PICHARD, L
    COMBALBERT, J
    BRESSOT, N
    BORIES, P
    MICHEL, H
    BEAUNE, P
    MAUREL, P
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (04) : 373 - 387
  • [57] CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines
    Gervot, L
    Carriere, V
    Costet, P
    Cugnenc, PH
    Berger, A
    Beaune, PH
    deWaziers, I
    [J]. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 1996, 2 (04) : 381 - 388
  • [58] GIBBS MA, 1997, ISSX P, V12, P157
  • [59] N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: Implications for inhibition of haemotoxicity
    Gill, HJ
    Tingle, MD
    Park, BK
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (06) : 531 - 538
  • [60] EXPRESSION OF CYTOCHROME-P450-3A5 IN ESCHERICHIA-COLI - EFFECTS OF 5' MODIFICATION, PURIFICATION, SPECTRAL CHARACTERIZATION, RECONSTITUTION CONDITIONS, AND CATALYTIC ACTIVITIES
    GILLAM, EMJ
    GUO, ZY
    UENG, YF
    YAMAZAKI, H
    COCK, I
    REILLY, PEB
    HOOPER, WD
    GUENGERICH, FP
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1995, 317 (02) : 374 - 384